Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for REGENXBIO Inc. (RGNX : NSDQ)

• Company Description    REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. Number of Employees: 353

• Price / Volume Information    Yesterday's Closing Price: $8.68 Daily Weekly Monthly 20 Day Moving Average: 742,737 shares Shares Outstanding: 50.16 (millions) Market Capitalization: $435.39 (millions) Beta: 1.06 52 Week High: $15.36 52 Week Low: $5.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.36% -10.60% 12 Week 46.13% 23.32% Year To Date 12.29% 5.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9804 MEDICAL CENTER DRIVE - ROCKVILLE,MD 20850 USA ph: 240-552-8181 fax: - ir@regenxbio.com http://www.regenxbio.com

• General Corporate Information    Officers Curran Simpson - Chief Executive Officer; President and Director Kenneth T. Mills - Chairman of the Board of Directors Mitchell Chan - Chief Financial Officer Jean Bennett - Director Allan M. Fox - Director Peer Information REGENXBIO Inc. (CORR.) REGENXBIO Inc. (RSPI) REGENXBIO Inc. (CGXP) REGENXBIO Inc. (BGEN) REGENXBIO Inc. (GTBP) REGENXBIO Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75901B107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 50.16 Most Recent Split Date: (:1) Beta: 1.06 Market Capitalization: $435.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.56 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 32.16% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.59 Price/Cash Flow: - Price / Sales: 2.78 EPS Growth vs. Year Ago Period: 108.70% vs. Previous Quarter: 111.88% Sales Growth vs. Year Ago Period: 469.79% vs. Previous Quarter: 319.59% ROE 06/30/25 - - 03/31/25 - -53.29 12/31/24 - -69.88 ROA 06/30/25 - - 03/31/25 - -30.84 12/31/24 - -41.60 Current Ratio 06/30/25 - - 03/31/25 - 2.93 12/31/24 - 2.69 Quick Ratio 06/30/25 - - 03/31/25 - 2.93 12/31/24 - 2.69 Operating Margin 06/30/25 - - 03/31/25 - -100.62 12/31/24 - -272.54 Net Margin 06/30/25 - - 03/31/25 - -100.62 12/31/24 - -272.54 Pre-Tax Margin 06/30/25 - - 03/31/25 - -100.62 12/31/24 - -272.54 Book Value 06/30/25 - - 03/31/25 - 5.47 12/31/24 - 5.24 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©